Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PYPD Stock Forecast 2025-2026
$3.53
Current Price
$35.97M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PYPD Price Targets
+324.9%
To High Target of $15.00
+282.4%
To Median Target of $13.50
+155.0%
To Low Target of $9.00
PYPD Price Momentum
+2.9%
1 Week Change
+25.6%
1 Month Change
-14.1%
1 Year Change
+16.1%
Year-to-Date Change
-21.4%
From 52W High of $4.49
+53.5%
From 52W Low of $2.30
📊 TOP ANALYST CALLS
Did PYPD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if PolyPid is one of their latest high-conviction picks.
Latest PYPD Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, PYPD has a bullish consensus with a median price target of $13.50 (ranging from $9.00 to $15.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $3.53, the median forecast implies a 282.4% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Boobalan Pachaiyappan at Roth Capital, suggesting a 155.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PYPD Analyst Ratings
4
Buy
0
Hold
0
Sell
PYPD Price Target Range
Low
$9.00
Average
$13.50
High
$15.00
Current: $3.53
Latest PYPD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PYPD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 17, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $14.00 |
| Jun 9, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Maintains | $13.00 |
| Jun 5, 2025 | Roth Capital | Boobalan Pachaiyappan | Buy | Initiates | $9.00 |
| Jun 2, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $11.00 |
| Apr 14, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $11.00 |
| Dec 26, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $11.00 |
| Dec 16, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Nov 4, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $10.00 |
| Oct 2, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $14.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $14.00 |
| Jun 18, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $14.00 |
| May 9, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $14.00 |
| May 1, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $14.00 |
| Oct 23, 2023 | Barclays | Balaji Prasad | Equal-Weight | Maintains | $10.00 |
| Oct 12, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $16.00 |
| Sep 7, 2022 | Barclays | Balaji Prasad | Equal-Weight | Downgrade | $2.50 |
| Sep 6, 2022 | Raymond James | Elliot Wilbur | Outperform | Downgrade | $4.00 |
| Aug 11, 2022 | BMO Capital | Gary Nachman | Outperform | Maintains | $25.00 |
| Feb 11, 2022 | Raymond James | Elliot Wilbur | Strong Buy | Maintains | $17.00 |
| Sep 14, 2021 | JMP Securities | Market Outperform | Initiates | $0.00 |
PolyPid Ltd. (PYPD) Competitors
The following stocks are similar to PolyPid based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PolyPid Ltd. (PYPD) Financial Data
PolyPid Ltd. has a market capitalization of $35.97M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -853.0%.
Valuation Metrics
Market Cap
$35.97M
Enterprise Value
$36.76M
P/E Ratio
0.0x
PEG Ratio
-1.3x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+22.4%
Current Ratio
0.7x
Debt/Equity
10,265.1x
ROE
-853.0%
ROA
-86.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
PolyPid Ltd. (PYPD) Business Model
About PolyPid Ltd.
What They Do
Develops innovative biopharmaceutical drug delivery systems.
Business Model
PolyPid Ltd. utilizes its proprietary PLEX technology platform to create localized drug delivery systems aimed at improving surgical outcomes. The company generates revenue through the development and commercialization of its lead product candidates, which target surgical site infections and tissue repair, thus addressing significant unmet medical needs in the healthcare market.
Additional Information
Operating within the biotechnology sector, PolyPid is positioned as a pioneer in biopharmaceutical research. The company aims to redefine post-operative care and infection management, attracting investor interest with its innovative approaches to healthcare solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
57
CEO
Ms. Dikla Czaczkes Akselbrad
Country
Israel
IPO Year
2020
Website
www.polypid.comPolyPid Ltd. (PYPD) Latest News & Analysis
Latest News
Quick Summary
PolyPid's D-PLEX100 demonstrated a 58% reduction in surgical site infections, highlighting its potential as a new standard of care, according to a PESG briefing.
Why It Matters
PolyPid's successful clinical trial and significant reduction in surgical site infections could lead to increased market share and revenue, enhancing investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
PolyPid's D-PLEX100 shows a 58% reduction in surgical site infections, potentially establishing it as a new standard of care, according to a PESG briefing.
Why It Matters
PolyPid's clinical success and significant reduction in surgical site infections could lead to increased market share and revenue, making it a promising investment opportunity in the healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
PolyPid Ltd. (Nasdaq: PYPD) announced positive topline results from its SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections in colorectal surgery, receiving FDA Fast Track designation.
Why It Matters
Positive Phase 3 trial results for D-PLEX100 indicate potential market approval and revenue growth for PolyPid, enhancing investor confidence and stock performance prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript
9 days ago
Quick Summary
PolyPid Ltd. reported positive topline results from its SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing surgical site infections in large abdominal colorectal surgeries.
Why It Matters
Positive Phase 3 trial results for D-PLEX100 suggest potential market approval, enhancing PolyPid's growth prospects and possibly driving stock prices higher.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
PolyPid Ltd. (Nasdaq: PYPD) will host a conference call on June 9 at 8:30 a.m. ET to report topline data from the SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections.
Why It Matters
The upcoming conference call on Phase 3 trial results for D-PLEX100 could significantly impact PolyPid's stock price, reflecting investor sentiment on its potential market success and therapeutic efficacy.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
PESG Research reports that PolyPid is addressing the $10 billion annual cost of surgical site infections with its innovative PLEX technology.
Why It Matters
PolyPid's PLEX technology addresses a significant market for surgical site infections, potentially unlocking substantial revenue and impacting its stock valuation positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PYPD Stock
What is PolyPid Ltd.'s (PYPD) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, PolyPid Ltd. (PYPD) has a median price target of $13.50. The highest price target is $15.00 and the lowest is $9.00.
Is PYPD stock a good investment in 2025?
According to current analyst ratings, PYPD has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PYPD stock?
Wall Street analysts predict PYPD stock could reach $13.50 in the next 12 months. This represents a 282.4% increase from the current price of $3.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is PolyPid Ltd.'s business model?
PolyPid Ltd. utilizes its proprietary PLEX technology platform to create localized drug delivery systems aimed at improving surgical outcomes. The company generates revenue through the development and commercialization of its lead product candidates, which target surgical site infections and tissue repair, thus addressing significant unmet medical needs in the healthcare market.
What is the highest forecasted price for PYPD PolyPid Ltd.?
The highest price target for PYPD is $15.00 from at , which represents a 324.9% increase from the current price of $3.53.
What is the lowest forecasted price for PYPD PolyPid Ltd.?
The lowest price target for PYPD is $9.00 from Boobalan Pachaiyappan at Roth Capital, which represents a 155.0% increase from the current price of $3.53.
What is the overall PYPD consensus from analysts for PolyPid Ltd.?
The overall analyst consensus for PYPD is bullish. Out of 9 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.50.
How accurate are PYPD stock price projections?
Stock price projections, including those for PolyPid Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 18, 2025 3:16 PM UTC